Oesophageal Cancer Clinical Trials
Oesophageal Cancer
Learn More About Oesophageal Cancer
For general information on oesophageal cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| ADCE-B05-001 | Oesophageal Cancer | A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients with Advanced Solid Tumors | Immunotherapy | ADC | Open - Recruiting | Adcendo ApS | NCT07362888 | Enquire Now |
| ADCE-T02-01 | Oesophageal Cancer | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| SL-28-FIH | Oesophageal Cancer | A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours | Immunotherapy | IV allogeneic, non-genetically modified cell-based therapy | Open - Recruiting | Second Life Therapeutics Pty Ltd. | ACTRN12625001342404p | Enquire Now |